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ABSTRACT
Expression of short hairpin RNAs via the use
of PolIII-based transcription systems has proven
to be an effective mechanism for triggering RNAi
in mammalian cells. The most popular promoters
for this purpose are the U6 and H1 promoters since
they are easily manipulated for expression of
shRNAs with defined start and stop signals.
Multiplexing (the use of siRNAs against multiple
targets) is one strategy that is being developed
by a number of laboratories for the treatment of
HIV infection since it increases the likelihood of
suppressing the emergence of resistant virus in
applications. In this context, the development of
alternative small PolIII promoters other than U6 and
H1 would be useful. We describe tRNA
Lys3-shRNA
chimeric expression cassettes which produce
siRNAs with comparable efficacy and strand selec-
tivity to U6-expressed shRNAs, and show that their
activity is consistent with processing by endog-
enous 30 tRNAse. In addition, our observations
suggest general guidelines for expressing effective
tRNA-shRNAs with the potential for graded
response, to minimize toxicities associated with
competition for components of the endogenous
RNAi pathway in cells.
INTRODUCTION
Suppression of HIV-1 replication has been achieved
through siRNAs directed against numerous targets
including the TAR element, the 30 UTR, vif, gag, tat,
rev and reverse transcriptase (RT) transcripts, as well
as the HIV-1 cellular co-receptor CCR5 [recently reviewed
in (1–7)]. While these results are encouraging, many
challenges still remain in developing eﬀective HIV-1 gene
therapeutics. Of particular concern is the ability of HIV-1
to rapidly evolve resistance to RNAi, especially as
siRNAs are sensitive to single base-pair mismatches.
Careful design and optimization of anti-viral siRNAs
increase the probability of circumventing resistance in
therapeutic applications. Potential RNAi-related prob-
lems include oﬀ-target eﬀects, immunostimulation and
interference with cellular microRNA pathways by com-
petition for transport, processing or RISC loading.
Choosing highly conserved HIV-1 regions as targets
increases the likelihood that RNAi-resistant variants will
be less ﬁt. Multiplexing (the use of siRNAs against
multiple conserved targets) further increases the like-
lihood of suppressing the emergence of viral variants, but
must be balanced against the possibility of compromising
cellular metabolism.
Expressing shRNAs from tRNA promoters has several
potential advantages in this context, compared to the
more commonly used U6 and H1 promoters: tRNA
promoters are smaller, provide a variety of options
and are typically expressed at lower levels. Smaller
promoters ease multiplexing in delivery vectors with size
constraints; expanding the number of promoter options
eases diﬃculties associated with repeated use of the same
promoter within a multiplex construct, and possible
recombination. In addition, lower expression levels may
allow multiplexing anti-HIV RNAi constructs with a
lower probability of interference with endogenous RNAi
pathways. Controlling the levels of shRNA expression
appears to be an increasingly important consideration for
therapeutic applications since sustained high-level expres-
sion of shRNAs can lead to toxicity via competition with
components of the endogenous RNAi machinery and
perhaps increased oﬀ-targeting (8,9).
To address the challenge of creating a simpliﬁed PolIII
expression system that can be used in combination with,
or in place of the existing U6 and H1 promoters,
we designed a tRNA
Lys3-shRNA chimera expression
construct targeting a highly conserved sequence in an
exon common to both tat and rev, previously shown to be
an eﬀective target when the same shRNA was expressed
by the U6 promoter (10,11).
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optimize the eﬀectiveness of tRNA
Lys3-shRNA chimeras
while minimizing oﬀ-target eﬀects. We have developed a
series of tRNA
Lys3-shRNA chimeric constructs which
exhibit a graded set of functional activities that should
prove useful for a variety of shRNA expression appli-
cations. Our studies also deﬁne critical features of the
tRNA sequence that result in eﬀective processing of the
shRNAs for further processing into siRNAs.
MATERIALS AND METHODS
Plasmid construction
tRNA
Lys3-tat/rev shRNA expression vectors. Cloning
of the U6-tat/rev shRNA was previously described (11).
The details of cloning and all DNA oligomers used in this
study are listed in the Supplementary Data, but a brief
description is included here.
tRNA
Lys3-tat/rev shRNA BsrG1 loop constructs were
cloned as follows. A PCR product encoding the tRNA
and tat/rev hairpin sense strand and loop was generated
using a (1) 50 primer and template speciﬁc to either the S4
or wild-type tRNA; the 50 primer adds a SalI site immedi-
ately upstream of the 50 end of the mature tRNA
Lys3
sequence and (2) a series of 30 primers that introduce a
given acceptor stem/DNt combination as well as the
hairpin sense/BsrG1 loop sequences. The PCR products
were digested with SalI and BsrG1 and gel puriﬁed as
previously described (11). Two additional complementary
oligomers having BsrG1 and PstI overhangs at the 50 and
30 ends (after annealing) encode the remainder of the
hairpin loop, anti-sense stem and PolIII termination
sequences (which is identical in all of the BsrG1 loop
constructs). The PCR products and annealed oligos
were ligated into the SalI and PstI sites of pBluescript
(Stratagene, USA).
tRNA
Lys3-tat/rev shRNA DC loop constructs were
cloned as follows. tRNA
Lys3 vectors were generated by
PCR as above, only using a series of 30 primers that add
either a BssHII or NruI site followed by a HindIII site in
the tRNA
Lys3 acceptor stem sequence. The PCR product
was digested with SalI and HindIII and cloned into the
same sites of pBluescript. Annealed oligos with BssHII or
NruI 50 termini and PstI 30 termini that code for the
remainder of the tRNA
Lys3 acceptor stem, entire tat/rev
shRNA hairpin and RNA pol3 termination signal
were ligated into the cognate sites of the appropriate
tRNA
Lys3 vector.
Luciferase reporter vectors. Complementary DNA oligo-
mers designed to have 50 XhoI and 30 XbaI overhangs
after annealing were synthesized for either the tat/rev sense
or anti-sense target regions, and inserted into the
XhoI and XbaI sites in the 30 UTR of Renilla luciferase
(R-luc) of the psiCHECK-2 dual reporter plasmid
(Promega, USA). The correct sequence of all constructs
was conﬁrmed by DNA sequencing at the City of Hope
Sequencing Core.
Tissue culture, transfections and dualluciferase assays
HCT116 colon carcinoma cells (CCL-247) or HEK-293
embryonic kidney ﬁbroblast cells (CCL-1573) were
obtained from the American Type Culture Collection
(USA), and grown in DMEM high glucose (Irvine
Scientiﬁc, USA) supplemented with 10% fetal bovine
serum (FBS) and 1.5mM L-glutamine (Irvine Scientiﬁc,
USA) and 10mM pyruvate (Irvine Scientiﬁc, USA).
Cells were cultured in a humidiﬁed 5% CO2 incubator
at 378C.
For dual luciferase assays, HCT116 or 293 cells
were seeded in 48-well culture dishes and transfected
the next day at  90% conﬂuency using Lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
instructions. For each well, a total of 160ng DNA
(see below) in 20ml OptiMEM was combined with
an equal amount of diluted (2.0ml/100ml OptiMEM)
Lipofectamine 2000. The incubation medium was
removed from the cells and the DNA–lipofectamine
mixture was added immediately, followed by 160mlo f
complete medium. At 18h post-transfection, the cell
medium was replaced with 200ml fresh medium and
culture continued for another 6h. Dual luciferase assays
were performed according to the manufacturer’s instruc-
tions (Promega, USA) 24h post-transfection. All samples
were transfected in duplicate or triplicate and the
experiment was performed a minimum of three times.
For psiCHECK dual luciferase transfections, DNA
mixtures contained 40ng of psiCHECK target derivative,
40ng of test or control plasmid and 80ng pBluescript
(carrier plasmid) in 20ml OptiMEM. Negative controls,
used for normalization, contained a plasmid with the
U6 or tRNA promoter for each psiCHECK target tested.
The U6-tat/rev shRNA construct was used as a positive
control. For each replicate, the R-luc target reading
was normalized internally to the F-luc value, and an
average calculated from the replicates. The average
for each hairpin construct was then normalized to the
value calculated from the appropriate empty promoter
(S4tRNA
Lys3,( þ)tRNA
Lys3 or U6) and target (sense or
anti-sense) combination in the same experiment. The
averages from independent experiments were then used
to calculate the values and standard deviations shown in
the ﬁgures.
pNL4-3.Luc.R .E  (NIH AIDS Research and
Reference Reagent Program, Germantown, MD) is
a Env  Vpr  non-infectious clone containing the ﬁreﬂy
luciferase (F-luc) gene inserted into the nef gene.
Transfections contained a ﬁnal combination of 40ng of
pNL4-3.Luc.R .E , 0.2ng of pRSV-Renilla, 40ng of test
or control plasmid and 80ng pBluescript (carrier plasmid)
in 20ml OptiMEM. For each replicate, the F-luc target
reading was normalized to the R-luc internal control, and
an average calculated from the replicates. The average
for each hairpin construct was then normalized to the
value calculated using the appropriate empty promoter
(S4tRNA
Lys3,( þ)tRNA
Lys3 or U6) in the same experi-
ment. The averages from independent experiments were
then used to calculate the values and standard deviations
shown in the ﬁgures.
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HCT116 and HEK 293 cells were cultured and transfected
as above for dual luciferase assays with the following
modiﬁcations. (1) Transfections were scaled up to 60mm
dishes. (2) To enhance detection of siRNA products, all
the transfected DNA consisted of the indicated construct
(as opposed to a 1:1:2 mixture of shRNA construct:target
construct:carrier pBluescript DNAs); consequently, 4-fold
more shRNA construct DNA was transfected per cell
for northern analysis, although the total amount of
transfected DNA per cell remained constant in both
assays. (3) Cells were incubated for 48h post-transfection
before isolating RNA, replacing the media at 18 and 42h
post-transfection. RNA was isolated from transiently
transfected cells using RNA STAT60 (Tel-Test, Inc.,
USA) following the manufacturer’s instructions. Twenty-
ﬁve micrograms of total RNA was electrophoresed on a
10% polyacrylamide–8M urea gel. RNA was transferred
to Hybond-Nþ membrane (Amersham Pharmacia
Biotech, USA) by electroblotting. Prehybridization and
hybridization were carried out using PerfectHyb Plus
Hybridization buﬀer (Sigma, USA) at 378C with 5pmol of
oligonucleotide probe end-labeled with T4 polynucleotide
kinase and g-
32P-ATP. Filters were washed twice with
100–150ml/cm
2with 5 SSPE/1% SDS at 378C for 15min,
then sequentially with 0.5–1.0ml/cm
2 with 2 SSPE/0.5%
SDS and 1 SSPE/0.5% SDS at 458C for 30–60min
each, prior to autoradiography or PhosphorImager
quantitation using ImageQuant software. Filters were
then re-hybridized with an end-labeled probe against U2
snRNA as a loading control, and autoradiography and
PhosphorImager quantitation repeated.
RESULTS
Previous studies in our laboratory demonstrated U6-tat/
rev shRNA (Figure 1A) to be a highly eﬀective inhibitor of
HIV replication in pNL 4–3 transient transfection assays
(10,11); consequently, we chose this same tat/rev shRNA
for the initial or ‘parental’ tRNA
Lys3-promoter construct,
S4tRNA
Lys3-tat/rev (Figure 1B and C), using a design
modeled on previously published tRNA
Lys3-anti-HIV
ribozyme chimeras [(12) and see below]. We initially
assayed these constructs using the psiCHECK reporter
system, which readily allows screening of the potencies of
candidate sh/siRNAs. The psiCHECK reporter system
has the advantage that knockdown of both the sense
target (corresponding to the mRNA) and the anti-sense
target can be assayed independently, and used as a
measure of the relative incorporation of each strand into
the RNA-induced silencing complex (RISC). This strand
selectivity is an important factor in evaluating shRNAs;
for instance, eﬃcacy against the desired target may suﬀer,
due to competition by the sense (passenger) strand
with the anti-sense (guide) strand for RISC entry. Of
equal concern, oﬀ-target eﬀects are greater with shRNAs
that eﬃciently incorporate the passenger strand due
to unfavorable thermodynamics or structure. Oﬀ-target
eﬀects confuse interpretation of downstream events in
biological or genetic applications of RNAi and potentially
compromise patient health in therapeutic applications
of RNAi. In practice, it is informative to measure both
the total eﬃcacy (knockdown of the sense target
corresponding to the mRNA) and the strand selectivity
(the ratio of sense target:anti-sense target knockdown)
when evaluating shRNAs.
Our initial comparison demonstrated that, as expected,
the U6-tat/rev shRNA is highly eﬀective, mediating  95%
knockdown of the sense target; however, knockdown of
the anti-sense target is much less, indicative of good strand
selection (Figure 2, lane 1). In contrast, the parental
S4tRNA
Lys3-tat/rev shRNA has poorer eﬃcacy (580%)
and strand selectivity, targeting the anti-sense strand
nearly equally (Figure 2, lanes 1 and 4). If
S4tRNA
Lys3-tat/rev were less eﬃcient at targeting the
sense strand, but had a comparable anti-sense:sense target
ratio as U6-tRNA
Lys3-tat/rev the simplest interpretation
would be that the S4tRNA
Lys3 promoter produces the
same tat/rev shRNA as the U6 counterpart, but at lower
levels. This is not what we observe: moreover, previous
experiments suggest that the reduced eﬃcacy of
tRNA
Lys3-tat/rev shRNAs of this general design stemmed
in part from poor processing, although 21-mer guide
strand products were observed by Northern analysis (data
not shown). Since the U6 promoter transcribes a single
shRNA resulting in superior RNAi eﬃcacy and strand
selectivity, we considered the possibility that processing of
Figure 1. (A) tat/rev shRNA, as transcribed from the U6 promoter.
The hairpin orientation is sense–loop–anti-sense. In some derivatives,
additional nucleotides were changed in the loop as shown to create a
BsrG1 site for cloning convenience. (B) tRNA
Lys3-tat/rev shRNAs.
tRNA
Lys3 wild-type sequence is shown starting with the mature
tRNA
Lys3 50 end; arrows indicate SELEX-derived mutations in the
S4tRNA
Lys3 variant; link to base of tat-rev hairpin in (A) is shown
schematically. The double headed arrow indicates the location of
cleavage required to release the tat/rev hairpin with a sequence identical
to that in (A). The dashed box indicates the acceptor stem/DNt region
which was varied and shown in (C). (C) Acceptor stem/DNt variants.
Only mutated bases relative to wild-type are indicated; all constructs
lack the CCA linker between the discriminator nucleotide and the ﬁrst
base of the hairpin unless otherwise indicated. DNt-X indicates a
change of the predominant (G) discriminator nucleotide to the
indicated base. Third acceptor stem base-pair mutations relative to
wild-type are also shown. ‘W’: wild-type acceptor stem. The acceptor
stem/DNt nucluotide variants were constructed in both the SELEX4
(St4tRNA
Lys3) and wild-type (þ) tRNA
Lys3 backgrounds.
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Lys3-shRNA construct was produc-
ing related, but poorer RNAi eﬀectors than the U6
hairpin, as opposed to the identical hairpin at lower levels.
This seemed reasonable since it is known that minor
changes, such as hairpin leader sequences and single
nucleotide shifts in target sequences between related
siRNAs, can have a large impact on RNAi-mediated
target knockdown. If so, then strand selectivity and
possibly eﬃcacy might improve if the same shRNA
could be processed from the S4tRNA
Lys3-tat/rev shRNA
chimera as produced by the U6 promoter (Figure 1A).
We next considered the possibility that if these
conjectures were correct, re-examination of the parental
S4tRNA
Lys3-tat/rev shRNA chimera characteristics
might be useful. Brieﬂy, the parental S4tRNA
Lys3-tat/rev
shRNA hybrid design was based upon the tRNA
Lys3-PBS
ribozyme chimeras (12) consisting of: a SELEX-derived
tRNA
Lys3 variant (S4tRNA
Lys3); a CCA linker (mimick-
ing the sequence added posttranscriptionally during
normal tRNA biogenesis prior to aminoacylation);
and an anti-HIV-1ribozyme directed against the sequence
immediately adjacent to the HIV-1 primer binding
sequence (PBS) recognized by the 30 end of cellular
tRNA
Lys3, the obligate primer for HIV-1 reverse trans-
cription. The S4tRNA
Lys3 variant contains a total of ﬁve
mutations (Figure 1B). The ﬁrst two mutations, A14G
and A21G, aﬀect tRNA-invariant D-loop nucleotides;
the third A57G is a conservative (purine–purine) change
of a semi-invariant position in the TC-loop. The
S4tRNA
Lys3-PBS ribozyme (S4tRNA
Lys3-Rz) maintains
4–6-fold higher steady-state levels of expression in
transient transfections than the corresponding wild-type
tRNA
Lys3-Rz (data not shown). We have not determined
if this is due to higher transcription levels, since A14 and
A57 occur in promoter A and B boxes, respectively, or
to a longer half-life since the invariant bases A14 and A21
are involved in tertiary interactions. The fourth mutation
G70U changes the third 3:70 base pair (bp) of the acceptor
stem from C:G to C:U. The ﬁfth mutation changes
the discriminator nucleotide (DNt), which serves as an
identity element for recognition by the corresponding
aminoacyl-tRNA synthetase from G to A (G73A); only
3/15 of the known human nuclear tRNA
Lys3 genes have A
as the DNt (http://lowelab.ucsc.edu/GtRNAdb) (13).
The processing mechanism producing 21-mer tat/rev
eﬀector sequences from the S4tRNA
Lys3-tat/rev shRNA
hybrid was unclear; however, one possible candidate was
the cellular machinery for processing endogenous pre-
cursor tRNAs, particularly the enzyme involved in the
removal of 30 trailers. We reevaluated our initial design in
the light of what is known about this enzyme, tRNAse
Z
L. tRNAse Z
L is a 30tRNAse that cleaves pre-tRNA
30 trailers immediately after the DNt (in most cases),
which is the ﬁrst unpaired base after the acceptor stem,
prior to addition of the CCA sequence [reviewed in (14);
Figure 1B]. In vitro assays demonstrate that inclusion of
the CCA sequence in pre-tRNA-like substrates inhibits
the 30 tRNAse processing enzyme tRNAse Z
L in higher
eukaryotes (15–17). The tRNA
Lys3 moiety of the parental
chimera contains a CCA linker after the DNt, which
would potentially inhibit tRNAse Z
L activity. The SELEX
mutations aﬀect the base pairing in the acceptor stem and
potentially alter the tertiary structure of the pre-tRNA;
similar changes in this stem can inhibit tRNAse Z
L
processing (see the Discussion section). Therefore, we
decided to test the hypothesis that redesigning the
tRNA
Lys3-tat/rev shRNA chimeras to be better substrates
of tRNAse Z
L would improve eﬃcacy and strand selec-
tivity of the shRNA, as measured by the psiCHECK
reporter assays already described. We expected that more
eﬃcient processing of the chimera would increase sense
target knockdown, which we refer to as eﬃcacy (provided
strand selectivity were not highly compromised). Good
strand selectivity, i.e. a high ratio of sense:anti-sense target
knockdown, would be consistent with release of the
shRNA by speciﬁc cleavage after the DNt, since it
would produce the same hairpin structure as the U6
promoter. Poor strand selectivity would be indicative of
the production of other, less eﬃcacious products, either by
tRNAseZ
L or some other cellular process.
In order to test this concept, we evaluated the eﬀect of
systematically reverting the SELEX mutations in the
tRNA
Lys3 moiety of the shRNA ‘parental’ chimera, using
the psiCHECK reporter system as an endpoint assay. We
began by ﬁrst addressing the mutations in the acceptor
stem and DNts, as well as the eﬀect of the CCA sequence.
Speciﬁcally (Figure 1C), we constructed a series of
S4tRNA
Lys3-based-tat/rev shRNAs where we eliminated
the CCA, known to inhibit tRNAse Z
L cleavage of
Figure 2. tat/rev shRNA activity and strand selectivity of acceptor
stem/DNt variants on the S4tRNA
Lys3 background. Dual luciferase
assays of psiCHECK sense (open bars) and anti-sense (ﬁlled bars)
targets are shown. All constructs are normalized to the value of the
corresponding empty promoter construct (S4tRNA
Lys3 or the U6) in
combination with the relevant target (sense or anti-sense). All tat/rev
hairpins contain the BsrG1 loop except where an asterix ( ) denotes the
DC loop. P (Lane 3) indicates a mutant tat/rev shRNA carrying
a deletion () of nucleotide 10 of the tat/rev hairpin passenger (P)
strand, which has no activity on the anti-sense substrate. The sequence
of the tRNA acceptor stem and discriminator nucleotide (Figure 1B
and C) is shown above each construct. (Lane 1) U6 tat/rev shRNA (DC
loop). (Lane 2) U6 tat/rev shRNA (BsrG1 loop). (Lane 3) S4tRNA
Lys3-
3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop) P. (Lane 4)
S4tRNA
Lys3-3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop).
(Lane 5) S4tRNA
Lys3-3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop).
(Lane 6) S4tRNA
Lys3-3:70C:U tat/rev shRNA (BsrG1 loop). (Lane 7)
S4tRNA
Lys3-DNt-A tat/rev shRNA (BsrG1 loop). (Lane 8)
S4tRNA
Lys3-W tat/rev shRNA (BsrG1 loop). (Lane 9) S4tRNA
Lys3-
DNt-U tat/rev shRNA (BsrG1 loop). (Lane 10) S4tRNA
Lys3-DNt-C
tat/rev shRNA (BsrG1 loop).
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the mutant U70 base back to G, restoring the wild-type
3:70C:G pairing of third acceptor stem base-pair from the
mutant C:U or (2) reverted the A73 base DNt-A, back to
the original DNt-G or (3) reverted both. In addition, we
constructed versions DNt-C and DNt-U which have the
remaining possible DNts (with a restored acceptor stem
3:70C:G pair). The ﬁrst three SELEX mutations, A14G,
A21G and A57G were retained; this is referred to as the
‘SELEX background’ indicated as S4tRNA
Lys3. We tested
this ﬁrst set of constructs in parallel with the ‘parental’
S4tRNA
Lys3 tat/rev shRNA and U6-tat/rev shRNAs
(Figure 2).
As shown in the reporter assays (Figure 2), mere
removal of the CCA did not increase eﬃcacy (knockdown
of the sense target) or enhance strand selectivity (Figure 2,
lanes 4 and 5). Eﬃcacy was most improved by restoration
of the third acceptor stem Watson–Crick base-pairing
(Figure 2, lanes 7–10), although not to levels obtained by
the corresponding U6 constructs (Figure 2, lanes 1 and 2).
However, any DNt besides G compromised strand selec-
tivity; only restoration of the wild-type G DNt reduced
knockdown of the anti-sense strand to approximately the
same absolute value as seen in the U6 constructs (Figure 2,
lanes 1, 6 and 8), although the eﬃcacy was still somewhat
compromised relative to U6 tat/rev shRNA.
Next, we tested the eﬀects of the remaining SELEX
mutations by reverting the ﬁrst three A14G, A21G and
A57G SELEX mutations back to wild-type (referred to as
the wild-type or (þ)tRNA
Lys3 background) in combina-
tion with the same series of acceptor stem/DNt variants
(Figure 3). As with the previous series, eﬃcacy and strand
selectivity were not improved by removal of the CCA
alone (Figure 3, lanes 2 and 3). Eﬃcacy was again
improved by restoration of the third Watson–Crick
acceptor stem base-pairing in most cases (Figure 3, lanes
4, 6–8); however, the A DNt compromised eﬃcacy but not
strand selectivity in this background (Figure 3, lanes 5–8).
The most striking result was that the completely wild-type
tRNA
Lys3-tat/rev shRNA construct had identical eﬃcacy
and strand selectivity as the corresponding U6 version in
this assay (Figure 3, lane 6), and the DNt-U and DNt-C
variants were nearly as good (Figure 3, lanes 7 and 8).
We compared additional acceptor stem variant
tRNA
Lys3 tat/rev shRNAs on both backgrounds in
psiCHECK dual luciferase assays; speciﬁcally, the
wild-type third 3:70C:G acceptor stem base-pair was
altered to C:C or G:C (G:C ﬂip), We also tested tat/rev
shRNAs with two slightly diﬀerent hairpin loops, referred
to as the ‘DC’ and ‘BsrG1’ loops (Figure 1A). On
the S4tRNA
Lys3 background, the acceptor stem third
base-pair C:C mismatch (Figure 4, lane 4) had the
same knockdown proﬁle as the C:U mismatch (Figure 2,
lane 6), compromising sense strand knockdown, not
strand selectivity. However, restoration of the canonical
Watson–Crick base-pairing, even in the ﬂipped orien-
tation, restored eﬃcacy (Figure 4, lane 5). The same
general pattern was observed in the wild-type tRNA
Lys3
background (Figure 4, lanes 8–10).
These trends were even more obvious in a diﬀerent
dual luciferase assay system. In our hands, knockdown of
Figure 4. Eﬀect of the acceptor stem third base-pair variants on tat/
rev shRNA functional activity and strand-selectivity in both the
S4tRNA
Lys3 and (þ)tRNA
Lys3 backgrounds. Dual luciferase assays of
psiCHECK sense (open bars) and antisense (ﬁlled bars) targets. All
constructs are normalized to the value of the corresponding empty
promoter construct (S4tRNA
Lys3 or the U6) in combination with the
relevant target (sense or anti-sense). All tat/rev hairpins contain
the BsrG1 loop except where an asterix ( ) denotes the DC loop.
(Lane 1) U6 tat/rev shRNA (DC loop). (Lane 2) S4tRNA
Lys3-
3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop). (Lane 3) S4tRNA
Lys3-
W tat/rev shRNA (BsrG1 loop). (Lane 4) S4tRNA
Lys3-3:70C:C tat/rev
shRNA (DC loop). (Lane 5) S4tRNA
Lys3-3:70G:C ﬂip/DNt-A
tat/rev shRNA (DC loop). (Lane 6) (þ)tRNA
Lys3-3:70C:U/DNt-A
tat/rev shRNA (BsrG1 loop). (Lane 7) (þ)tRNA
Lys3-W tat/rev shRNA
(BsrG1 loop). (Lane 8) (þ)tRNA
Lys3-W tat/rev shRNA (DC loop).
(Lane 9) (þ)tRNA
Lys3-3:70C:C tat/rev shRNA (DC loop). (Lane 10)
(þ)tRNA
Lys3-3:70G:C ﬂip/DNt-A tat/rev shRNA (DC loop).
Figure 3. tat/rev shRNA activity and strand selectivity of acceptor
stem/DNt variants in the wild-type (þ)tRNA
Lys3 background.
Dual luciferase assays of psiCHECK sense (open bars) and anti-sense
(ﬁlled bars) targets. All constructs are normalized to the value of the
corresponding empty promoter construct (S4tRNA
Lys3 or the U6) in
combination with the relevant target (sense or anti-sense). All tat/rev
hairpins contain the BsrG1 loop except where an asterix ( ) denotes the
DC loop. (Lane 1) U6 tat/rev shRNA (DC loop). (Lane 2)
(þ)tRNA
Lys3-3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop).
(Lane 3) (þ)tRNA
Lys3-3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop).
(Lane 4) (þ)tRNA
Lys3-3:70C:U tat/rev shRNA (BsrG1 loop). (Lane 5)
(þ)tRNA
Lys3-DNt-A tat/rev shRNA (BsrG1 loop). (Lane 6)
(þ)tRNA
Lys3-W tat/rev shRNA (BsrG1 loop). (Lane 7) (þ)tRNA
Lys3-
DNt-U tat/rev shRNA (BsrG1 loop). (Lane 8) (þ)tRNA
Lys3-DNt-C
tat/rev shRNA (BsrG1 loop).
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minimizing potential diﬀerences in sh/siRNA eﬃcacy
that reﬂect more accurately their performance in more
biologically relevant applications. We therefore replicated
these assays using a non-infectious HIV pNL4-3 luc
reporter, containing a ﬁreﬂy luciferase-coding sequence
inserted into the viral 30 UTR (18,19). Unlike the
psiCHECK reporter, which produces a single target
transcript, pNL4-3 luc produces multiple HIV-1 tran-
scripts which share a common 30 UTR containing the
luciferase-coding sequences. Any tat or rev transcripts that
escape RNAi-mediated degradation allow expression of
downstream viral messages, which all express the reporter
but not necessarily the tat/rev target sequence. In practice,
diﬀerences in tat and rev knockdown that are diﬃcult to
detect in the psiCHECK system are more obvious in the
pNL4-3 luc reporter system. As seen in the psiCHECK
assays, the acceptor stem third base-pair C:C mismatch
compromised eﬃcacy against the pNL4–3 luc target as
well, which was fully restored by the G:C ﬂip within both
tRNA
Lys3 backgrounds (Figure 5A; lanes 6, 7, 12 and 13).
However, the diﬀerences between the S4tRNA
Lys3 and
þS4tRNA
Lys3 backgrounds were much more evident (e.g.
Figure 5A; lane 8 versus 13). In addition, the sequence of
the tat/rev loop inﬂuenced eﬃcacy on the wild-type
(þ)tRNA
Lys3 background (Figure 5A; lanes 10 and 11).
Most importantly, two tRNA
Lys3-tat/rev shRNA con-
structs in the wild-type background achieved knockdown
levels comparable to the U6-tat/rev shRNA constructs
(Figure 5A; lanes 1, 2, 12 and 13).
To be generally applicable, these observations should
be reproducible in diﬀerent cell types. We repeated the
pNL4-3-luc reporter assays shown in Figure 5A in HEK
293 cells (Figure 5B) and observed the same general trends.
RNAi is mediated by  21-nt eﬀector complexes;
therefore, the tRNA
Lys3-shRNA constructs should gen-
erate products derived from the hairpin guide strand
of the same size. We carried out northern gel analyses
on total RNA extracted from both HCT116 and 293 cells
transiently transfected with subsets of our constructs
representing the best and worst knockdown proﬁles,
and hybridized the blots with probes against the guide
strand of the hairpin (Figure 6). In both cell types, the
relative levels of guide strand siRNA in the northern
analysis reﬂected the eﬃcacy of the construct in the dual
luciferase assays.
DISCUSSION
Endogenous nuclear and mitochondrial pre-tRNAs
undergo a multi-step maturation that includes removal
of the 50 leader sequence by RNAse P [reviewed in
(20–23)]; removal of the 30 trailer sequence by 30 tRNAse
endonucleolytic cleavage, typically immediately after the
discriminator base [reviewed in (24–26)]; and addition
of the CCA trinucleotide to the processed 30 end by the
CCA nucleotidyl-transferase (27) prior to aminoacylation.
In addition, tRNAs undergo many posttranscriptional
modiﬁcations (28–30). [See also (14,31) for overviews of
tRNA processing.]
The tRNA 30 processing enzyme, or tRNAse Z occurs
in long and short forms, tRNAse Z
L and tRNAse Z
S,
respectively; all eukaryotes have the long form, and
some have both [for nomenclature, see (24)]. The human
homologs HsatRNAse Z
S and HsatRNAse Z
L are
encoded by the related but separate genes ELAC1 and
ELAC2, respectively (32–34). Recombinant HsatRNAse
Z
L processes nuclear-encoded pre-tRNA 1600-fold more
A
B
Figure 5. Eﬀect of the acceptor stem third base-pair variants on tat/rev
shRNA functional activity and strand selectivity in both the
S4tRNA
Lys3 and (þ) tRNA
Lys3 backgrounds in the pNL4-3 luc
reporter assay in (A) HCT116 cells and (B) HEK293 cells. Open
bars: constructs with tat/rev shRNA DC loop. Gray ﬁlled bars:
constructs with tat/rev shRNA BsrG1 loop. All values are normalized
to the values obtained with the corresponding (þ) tRNA
Lys3,
S4tRNA
Lys3 or U6 empty promoter constructs. (Lane 1) U6 tat/rev
shRNA (DC loop). (Lane 2) U6 tat/rev shRNA (BsrG1 loop). (Lane 3)
S4tRNA
Lys3-3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop).
(Lane 4) S4tRNA
Lys3-3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop).
(Lane 5) S4tRNA
Lys3 -W tat/rev shRNA (BsrG1 loop). (Lane 6)
S4tRNA
Lys3-3:70C:C tat/rev shRNA (DC loop). (Lane 7) S4tRNA
Lys3-
3:70G:C ﬂip/DNt-A tat/rev shRNA (DC loop). (Lane 8) (þ)tRNA
Lys3-
3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop). (Lane 9)
(þ)tRNA
Lys3-3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop). (Lane
10) (þ)tRNA
Lys3 -W tat/rev shRNA (BsrG1 loop). (Lane 11)
(þ)tRNA
Lys3 -W tat/rev shRNA (DC loop). (Lane 12) (þ)tRNA
Lys3-
3:70C:C tat/rev shRNA (DC loop). (Lane 13) (þ)tRNA
Lys3-3:70G:C
ﬂip/DNt-A tat/rev shRNA (DC loop).
Nucleic Acids Research, 2007, Vol. 35, No. 8 2625eﬃciently than the short form, suggesting that it is the
predominant active form for processing endogenous
tRNAs when both forms are present in the genome
(35). Drosophila cells retain only the long form, which
processes nuclear and mitochondrial pre-tRNAs in vivo
and in vitro (36). Recombinant HsatRNAse Z
L, but not
HsatRNAse Z
S, contains a mitochondrial import signal,
and processes mitochondrial pre-tRNA substrates in vitro,
although with lower eﬃciency than nuclear pre-tRNAs
on the tested substrates (35,37).
We designed tRNA
Lys3-tat/rev shRNA chimeras taking
into account their potential as tRNAse Z
L substrates.
Accurate cleavage after the discriminator base will
produce the same hairpin as the U6 promoter, which
we used as the standard for optimal RNAi-mediated
knockdown eﬃciency and strand selectivity. Our studies
delineate some structural characteristics of tRNA
Lys3 that
inﬂuence the RNAi activity of the chimera, which we
consider in the context of what is currently known about
the activity of tRNAse Z
L.
Mismatches in the third base-pair (3:70) of the
tRNA
Lys3 acceptor stem reduce overall RNAi eﬃcacy,
but not strand selectivity in both wild-type and
the SELEX A14G/A21G/A57G mutant backgrounds.
This is consistent with reduced eﬃciency, but not reduced
accuracy of hairpin release from the tRNA
Lys3 chimeras
in these constructs. However, the acceptor stem need not
carry the exact wild-type sequence for full activity, as
constructs where the third acceptor stem base-pair
is ﬂipped from C:G to G:C are equivalent within the
same tRNA
Lys3 background. This result parallels the
negative eﬀects of acceptor stem mutations that alter
Watson–Crick base-pairing in mitochondrial tRNAs
(mt-tRNAs) on cleavage eﬃciency by HsatRNAse Z
L
(35,37–39). Similar eﬀects are seen with porcine tRNAse
Z activities on bipartite tRNA-like structures (40) and
Drosophila tRNAse Z
L on nuclear tRNA
His.
The negative eﬀects of the acceptor stem base-pair
mismatches are intensiﬁed in the SELEX A14G/A21G/
A57G mutant background, although only eﬃciency, not
strand selectivity, is compromised; this again is consistent
with a decrease in activity, rather than accuracy of
processing. The canonical tertiary tRNA U8-A14-A21
interaction may be adversely aﬀected in S4tRNA
Lys3
variant. In this context, it is interesting that the A3243G
mutation in mt-tRNA
Leu(UUR), corresponding to the
A14G mutation found in the S4tRNA variant, is pro-
cessed less eﬃciently by tRNAse Z
L in HeLa cell extracts
(37). This comparison is even more striking, given that of
all the mitochondrial tRNA families, tRNA
Leu(UUR)
retain the most classical structure, including all potential
tertiary interactions, unlike many mt-RNAs which often
diﬀer from the canonical nuclear tRNAs (28,41).
The CCA of mature tRNA is an anti-determinant
for eukaryotic tRNAse Z
L (15–17), preventing non-
productive and energetically expensive recycling of
addition and removal of the CCA triplet, impeding
subsequent aminoacylation. Our ‘parental’ constructs
contained a CCA linker between the DNt and the
tat/rev hairpin. Somewhat surprisingly, removal of the
CCA had no appreciable eﬀect, but we only tested CCA
removal in the context of the DNt G73A mutation and
C3:U70 acceptor stem mismatches, which may mask any
eﬀect of the CCA in these assays.
A
B
Figure 6. Processed siRNAs from tRNA
Lys3-tat/rev shRNAs. (A) Top:
Northern analysis of transiently transfected tRNA
Lys3-tat/rev shRNA
constructs in HCT116 cells, probed for tat/rev shRNA guide strand.
(M) Ambion decade marker, numbers indicate size in nucleotides.
(Lane 1) pBluescript. (Lane 2) U6-promoter. (Lane 3) S4tRNA
Lys3-PBS
ribozyme. (Lane 4) U6-tat/rev shRNA. (Lane 5) S4tRNA
Lys3-3:70C:U/
DNt-A/CCA tat/rev shRNA (BsrG1 loop). (Lane 6) S4tRNA
Lys3-
3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop). (Lane 7) S4tRNA
Lys3-
(W) tat/rev shRNA. (Lane 8) (þ)tRNA
Lys3-3:70C:U/DNt-A/CCA
tat/rev shRNA (BsrG1 loop). (Lane 9) (þ)tRNA
Lys3-3:70C:U/DNt-A
tat/rev shRNA (BsrG1 loop). (Lane 10) (þ)tRNA
Lys3-W tat/rev shRNA
(BsrG1 loop). (Lane 11) (þ)tRNA
Lys3-W tat/rev shRNA. (B) Northern
analysis of transiently transfected tRNA
Lys3-tat/rev shRNA constructs
in HEK 293 cells, probed for tat/rev shRNA guide strand. (M) Ambion
decade marker. (Lane 1) pBluescript. (Lane 2) U6-irrelevant shRNA.
(Lane 3) (þ)tRNA
Lys3-promoter. (Lane 4) U6(þ)tRNA
Lys3-PBS
ribozyme. (Lane 5) U6-tat/rev shRNA. (Lane 6) (þ)tRNA
Lys3-
3:70C:U/DNt-A/CCA tat/rev shRNA (BsrG1 loop). (Lane 7)
(þ)tRNA
Lys3-3:70C:U/DNt-A tat/rev shRNA (BsrG1 loop). (Lane 8)
(þ)tRNA
Lys3-(W) tat/rev shRNA. (Lane 9) (þ)tRNA
Lys3-3:70C:C
tat/rev shRNA (Lane 10).
2626 Nucleic Acids Research, 2007, Vol. 35, No. 8As a whole, our results are consistent with a model in
which cellular tRNAse Z
L cleaves tRNA
Lys3-tat/rev
shRNA chimeras immediately after the discriminator
base, in the same relative position as endogenous pre-
tRNAs, when the chimeras resemble a normal substrate,
releasing a tat/rev hairpin which functions in RNAi
equivalently to the U6 promoter product. This hypothesis
seems reasonable given that mammalian tRNAse Z
L is
capable of cleaving very minimal or unusual substrates
in vitro, though with varying eﬃciencies (40,42). Synthetic
or expressed small guide RNAs can cleave target
sequences in vivo that form tRNA-like structure in trans
both in vitro (43–46) and in vivo (44,47). Experiments are
underway to more directly determine if tRNAse Z
L is
actually responsible for processing tRNA-shRNA and
if the structure–function relationships observed in this
work generalize to other tRNA isotypes. A possible
application of our results is that tRNA-hairpin chimeras
could provide a rapid endpoint assay of the eﬀect of
tRNA mutations on pre-tRNA processing.
Our basic design is substantially diﬀerent than that of
previously reported tRNA
Val-based shRNAs (48,49).
In these studies, tRNA
Val was used only as a promoter
for the attached shRNA. The tRNA
Val sequence was
truncated after the B-box sequences, keeping only the ﬁrst
65nt intact; consequently, there is no acceptor stem
or DNt. Instead, the shRNA is tethered by a 25nt,
non-tRNA sequence. In that study, the authors did not
address issues of strand selectivity, design optimization or
the potential processing mechanism.
A feature of the chimeric tRNA
Lys3-shRNA chimeric
constructs, which is signiﬁcantly diﬀerent from that of
the U6-expressed shRNAs, is the fact that the hairpin is
processed from the primary transcript in the tRNA
Lys3
expression systems, whereas the U6 promoter results in
direct expression of intact hairpins which are exported
to the cytoplasm and processed by RISC. Since the
shRNAs in our constructs do not ﬁt the criteria for
Drosha/DGCR8 processing (50,51), the hairpin is most
probably released by tRNAseZ
L prior to export and RISC
processing.
In summary, we describe tRNA
Lys3-shRNAs with
comparable RNAi eﬃciency and strand selectivity to the
corresponding U6-driven shRNA, and determine some of
the parameters that inﬂuence the degree of and speciﬁcity
of knockdown, expanding the repertoire of promoters for
shRNA expression. Furthermore, the tRNA
Lys3 variants
we describe have the potential to mediate graded RNAi
knockdown (for example, Figure 5, lanes 7, 8 and 13).
This may be of value in avoiding the toxicity that can
arise in applications where using multiple shRNAs are
advantageous, such as interfering with HIV-1 replication.
Another possible application would be in modulating
knockdown of an in vivo target to produce intermediate
phenotypes in genetic studies.
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